| Identification | Back Directory | [Name]
Cdk1/2 Inhibitor III | [CAS]
443798-47-8 | [Synonyms]
K00546
K00546
(K 00546)
1H-1,2,4-Triazole-1-carbothioamide, 5-amino-3-[[4-(aminosulfonyl)phenyl]amino]-N-(2,6-difluorophenyl)- | [Molecular Formula]
C15H13F2N7O2S2 | [MDL Number]
MFCD09264159 | [MOL File]
443798-47-8.mol | [Molecular Weight]
425.44 |
| Chemical Properties | Back Directory | [Boiling point ]
649.1±65.0 °C(Predicted) | [density ]
1.72±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≤10mg/ml in DMSO | [form ]
solid | [pka]
6.61±0.70(Predicted) |
| Hazard Information | Back Directory | [Description]
Cyclin-dependent kinases (Cdks) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Cdk1/2 Inhibitor III is a cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin A (IC50s = 0.6 and 0.5 nM, respectively). It less potently inhibits CDC2-like kinases 1 and 3, VEGFR2, and GSK-3β (IC50s = 8.9, 29, 32, and 140 nM, respectively) and is without effect against a panel of other kinases. Cdk1/2 Inhibitor III blocks the growth of several cancer cell lines (IC50 values range from 20 to 92 nM). | [Uses]
Cdk1/2 Inhibitor III is a cyclin-?dependent kinase (CDK) inhibitor. Cdk1 and Cdk2 performs inhibitory activities, and in vitro cellular proliferation in various human tumor cells. | [in vitro]
cdk1/2 inhibitor iii was identified as a cell-permeable inhibitor of cdk1/cyclin b and cdk2/cyclin a and could less potently inhibit cdc2-like kinases 1 and 3, vegfr2, and gsk-3β. cdk1/2 inhibitor iii was found to be lack of effect against a panel of other kinases. moreover, cdk1/2 inhibitor iii could block the growth of various cancer cell lines (ic50 values range from 20 to 92 nm) [1]. | [in vivo]
the in-vivo efficacy of compound 3b, a structurally close cdk1/2 inhibitor iii analog, was examined in the a375 human melanoma cell xenograft model. doses at 125, 100, and 75 mg/kg were administered once a day for 32 days and tumor size was measured every 4 days. the results showed that in the 125 mg/kg group, there was one nontreatment-related death but the remaining four animals experienced stable disease. in addition, compound 3b administered at 100 and 75 mg/kg led to mean day of survival values of 50.1 and 48.5 days, respectively, with only one treatment-related death in the 100 mg/kg group [1]. | [IC 50]
0.6 and 0.5 nm forcdk1/cyclin b and cdk2/cyclin a, respectively | [References]
[1] lin, r. ,connolly, p.j.,huang, s., et al. 1-acyl-1h-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. journal of medicinal chemistry 48(13), 4208-4211 (2005). |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|